CancerDrs

Ovarian Cancer clinical trials in North Carolina

48 actively recruiting ovarian cancer trials at 31 sites across North Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in North Carolina:
  • Mission Hospital — Asheville, North Carolina
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Novant Health Presbyterian Medical Center — Charlotte, North Carolina
  • Oncology Specialists of Charlotte — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…

Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • Wake Forest University Health Sciences — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…

Sponsor: GOG Foundation
NCT ID: NCT05659381
Sites in North Carolina:
  • Duke Cancer Center — Durham, North Carolina
  • Duke Women's Cancer Care Raleigh — Raleigh, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in North Carolina:
  • Levine Cancer Center — Charlotte, North Carolina
  • Novant Presbyterian Hospital — Charlotte, North Carolina
  • East Carolina University — Greenville, North Carolina
  • Novant Health Oncology Specialists — Winston-Salem, North Carolina
  • Atrium Health Wake Forest Baptist — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Sites in North Carolina:
  • Duke Women's Cancer Care- Raleigh — Durham, North Carolina
  • Duke Cancer Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in North Carolina:
  • Atrium Health — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in North Carolina:
  • FirstHealth Cancer Center ( Site 0079) — Pinehurst, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…

Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in North Carolina:
  • Levine Cancer Institute — Charlotte, North Carolina
  • East Carolina University — Greenville, North Carolina
  • Atrium Health Wake Forest Baptist, Comprehensive Cancer Center — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…

Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Sites in North Carolina:
  • UNC Hospital — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Sites in North Carolina:
  • Duke — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in North Carolina:
  • Cone Health MedCenter Asheboro — Asheboro, North Carolina
  • Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
  • Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in North Carolina:
  • Site 0259 - Duke Cancer Center — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina:
  • Duke University — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…

Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in North Carolina:
  • Atrium Health Wake Forest Baptist - Comprehensive Cancer Center — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …

Sponsor: AbbVie
NCT ID: NCT07059845
Sites in North Carolina:
  • FirstHealth of the Carolinas- Speciality Center /ID# 278636 — Pinehurst, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in North Carolina:
  • Duke Cancer Center Durham — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in North Carolina:
  • Carolina BioOncology Institute — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmaco…

Sponsor: Incyclix Bio
NCT ID: NCT05735080
Sites in North Carolina:
  • Levine Cancer Institute (LCI)- Atrium Health — Charlotte, North Carolina
  • Duke Cancer Center/ DUMC — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The ma…

Sponsor: Compugen Ltd
NCT ID: NCT06888921
Sites in North Carolina:
  • Levine Cancer Institute — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of DM002 in Patients With Advanced Solid Tumors

The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling…

Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
NCT ID: NCT06751329
Sites in North Carolina:
  • Carolina BioOncology Institute, LLC — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

Sponsor: AstraZeneca
NCT ID: NCT05877599
Sites in North Carolina:
  • Research Site — Charlotte, North Carolina
  • Research Site — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in North Carolina:
  • Duke Cancer Institute /ID# 276267 — Durham, North Carolina
  • Carolina BioOncology Institute /ID# 232597 — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of PHST001 in Advanced Solid Tumors

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chem…

Sponsor: Pheast Therapeutics
NCT ID: NCT06840886
Sites in North Carolina:
  • Duke Cancer Institute — Durham, North Carolina
View on ClinicalTrials.gov →

Showing 25 of 48 trials with sites in North Carolina. See all ovarian cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01